Immunodiagnostic Systems Holdings PLC Sustainability Profile
Immunodiagnostic Systems Holdings PLC, commonly referred to as IDS, is a leading player in the immunodiagnostics industry, headquartered in the United Kingdom. Founded in 1977, IDS has established itself as a pioneer in the development and manufacture of innovative diagnostic solutions, primarily focusing on immunoassay technology for clinical laboratories. With a strong presence in Europe, North America, and Asia, IDS offers a diverse range of products, including automated immunoassay analysers and a comprehensive portfolio of assays. Their unique approach combines advanced technology with a commitment to quality, ensuring reliable and accurate results for healthcare professionals. Recognised for its significant contributions to the field, IDS has achieved notable milestones, including the expansion of its product line and strategic partnerships that enhance its market position. As a trusted name in immunodiagnostics, IDS continues to drive advancements in healthcare diagnostics.
DitchCarbon Score
How does Immunodiagnostic Systems Holdings PLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Immunodiagnostic Systems Holdings PLC's score of 46 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Immunodiagnostic Systems Holdings PLC, headquartered in Great Britain, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Revvity, Inc., and any climate commitments or emissions data would be cascaded from this parent organization. As of now, Immunodiagnostic Systems Holdings PLC has not established specific reduction targets or initiatives, nor does it appear to have made any formal climate pledges. The lack of documented emissions data and reduction initiatives suggests that the company may be in the early stages of developing its climate strategy. For context, the parent company, Revvity, Inc., may have its own sustainability goals and emissions data that could influence the subsidiary's future commitments. However, without specific information from Revvity, Inc. regarding their emissions or climate initiatives, it is challenging to provide a detailed overview of Immunodiagnostic Systems Holdings PLC's carbon footprint or climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 2,289,000 | 0,000,000 |
| Scope 2 | 29,844,000 | 00,000,000 |
| Scope 3 | - | - |
How Carbon Intensive is Immunodiagnostic Systems Holdings PLC's Industry?
How Carbon Intensive is Immunodiagnostic Systems Holdings PLC's Location?
Immunodiagnostic Systems Holdings PLC's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Immunodiagnostic Systems Holdings PLC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
